CollPlant Expands the Distribution of its VergenixSTR Product in Europe
CollPlant Biotechnologies (NASDAQ: CLGN) has announced the expansion of its European distribution network for Vergenix™ STR through a new agreement in Poland. The product, based on CollPlant's rhCollagen technology, is designed to treat various tendinopathies by combining with platelet-rich plasma (PRP) to form a scaffold that promotes tendon healing.
Vergenix™ STR targets multiple indications including tennis elbow, rotator cuff injuries, patellar tendinopathy, Achilles tendon injuries, and hand tendon repairs. The product creates a gel matrix that enables localized, sustained release of growth factors at injury sites. CollPlant expects to deliver the first shipment to its Polish distributor by the end of 2025.
CollPlant Biotechnologies (NASDAQ: CLGN) ha annunciato l'espansione della sua rete di distribuzione europea per Vergenix™ STR tramite un nuovo accordo in Polonia. Il prodotto, basato sulla tecnologia rhCollagen di CollPlant, è pensato per trattare diverse tendinopatie combinandosi con PRP (plasma ricco di piastrine) per formare una matrice di supporto che stimola la guarigione dei tendini.
Vergenix™ STR si propone per diverse indicazioni includendo gomito del giocatore (tennis elbow), lesioni della cuffia dei rotatori, tendinopatia rotulea, lesioni del tendine d'Achille e riparazioni di tendini della mano. Il prodotto crea una matrice a gel che permette il rilascio localizzato e sostenuto di fattori di crescita nei siti di infortunio. CollPlant prevede di spedire la prima fornitura al suo distributore polacco entro la fine del 2025.
CollPlant Biotechnologies (NASDAQ: CLGN) ha anunciado la expansión de su red de distribución europea para Vergenix™ STR mediante un nuevo acuerdo en Polonia. El producto, basado en la tecnología rhCollagen de CollPlant, está diseñado para tratar diversas tendinopatías al combinarse con plasma rico en plaquetas (PRP) para formar un andamaje que fomenta la curación del tendón.
Vergenix™ STR se dirige a múltiples indicaciones, incluyendo codo de tenista, lesiones del manguito rotador, tendinopatía patelar, lesiones del tendón de Aquiles y reparaciones de tendones de la mano. El producto crea una matriz de gel que permite la liberación localizada y sostenida de factores de crecimiento en los sitios de lesión. CollPlant espera entregar el primer envío a su distribuidor polaco a finales de 2025.
CollPlant Biotechnologies (NASDAQ: CLGN)는 폴란드에서의 새로운 계약을 통해 Vergenix™ STR의 유럽 유통 네트워크를 확장했다고 발표했습니다. 이 제품은 CollPlant의 rhCollagen 기술을 기반으로 하며 PRP(혈소판 풍부 혈장)와 결합해 건 회복을 촉진하는 지지체를 형성하도록 설계되었습니다.
Vergenix™ STR은 테니스 엘보, 어깨 회전근개 부상, 슬개건병, 아킬레스건 부상, 손힘줄 재건 등 여러 적응증을 대상으로 합니다. 이 제품은 부상 부위에서 성장 인자의 국소적이고 지속적인 방출을 가능하게 하는 젤 매트릭스를 생성합니다. CollPlant는 2025년 말 폴란드 유통사에 첫 선적을 보낼 계획입니다.
CollPlant Biotechnologies (NASDAQ: CLGN) a annoncé l'expansion de son réseau de distribution européen pour Vergenix™ STR via un nouvel accord en Pologne. Le produit, basé sur la technologie rhCollagen de CollPlant, est conçu pour traiter diverses tendinopathies en association avec le PRP (plasma riche en plaquettes) afin de former une matrice de soutien qui favorise la guérison des tendons.
Vergenix™ STR cible plusieurs indications incluant l’épicondyle latéral ( tennis elbow ), les lésions de la coiffe des rotateurs, la tendinopathie patellaire, les lésions du tendon d’Achille et les réparations des tendons de la main. Le produit crée une matrice gélifiée qui permet une libération localisée et soutenue des facteurs de croissance sur les sites de blessure. CollPlant prévoit d’expédier la première livraison à son distributeur polonais d’ici la fin de 2025.
CollPlant Biotechnologies (NASDAQ: CLGN) hat die Erweiterung seines europäischen Vertriebsnetzes für Vergenix™ STR durch eine neue Vereinbarung in Polen angekündigt. Das Produkt, basierend auf CollPlants rhCollagen-Technologie, soll verschiedene Tendinopathien behandeln, indem es mit plättchenreichem Plasma (PRP) kombiniert wird, um ein Gerüst zu bilden, das die Heilung der Sehnen fördert.
Vergenix STR zielt auf mehrere Indikationen ab, darunter Tennisarm, Rotatorenmanschetten-Verletzungen, Patellaspandendinopathie, Achillessehnenverletzungen und Handsehnen-Reparaturen. Das Produkt erzeugt eine Gelmatrix, die eine lokalisierte, nachhaltige Freisetzung von Wachstumsfaktoren an den Verletzungsstellen ermöglicht. CollPlant erwartet, die erste Lieferung bis Ende 2025 an seinen polnischen Distributor zu senden.
CollPlant Biotechnologies (NASDAQ: CLGN) أعلنت عن توسيع شبكة توزيعها الأوروبية لـ Vergenix™ STR من خلال اتفاقية جديدة في بولندا. المنتج، المستند إلى تقنية rhCollagen من CollPlant، مصمم لعلاج عدد من التهابات الأوتار بالتعاون مع PRP (زَمِّة البلازما الغنية بالصفائح الدموية) لتشكيل هيكل داعم يعزز الشفاء في الأوتار.
يستهدف Vergenix STR عدة مؤشرات بما في ذلك الكوع الرياضي، إصابات الكفة المدورة، التهاب وتر الرضفة، إصابات وتر أخيل، وإصلاح أوتار اليد. يكوّن المنتج مصفوفة هلامية تسمح بإطلاق محلي ومستمر لعوامل النمو في مواقع الإصابة. تتوقع CollPlant تسليم الشحنة الأولى إلى موزعها البولندي بنهاية عام 2025.
CollPlant Biotechnologies (NASDAQ: CLGN)宣布通过在波兰达成新协议，扩大其在欧洲的Vergenix™ STR分销网络。该产品基于CollPlant的 rhCollagen 技术，旨在与富血小板血浆（PRP）结合，形成有助于促进肌腱愈合的支架。
Vergenix™ STR 针对多种适应症，包括 网球肘、肩袖损伤、髌腱病、跟腱损伤以及手部肌腱修复。该产品创建一种凝胶基质，使在伤处实现局部、持续释放生长因子。CollPlant 预计在2025年年底前向其波兰分销商交付第一批货物。
- Expansion into new European market through Polish distribution agreement
- Product addresses multiple tendon injury indications
- Strategic partnership with Allergan (AbbVie) for dermal and soft tissue fillers exists since 2021
- Company has a history of significant losses as mentioned in risk factors
- Requires additional capital raising which may not be obtained on acceptable terms
Insights
CollPlant expands VergenixSTR distribution into Poland, enhancing European presence for its innovative tendon repair technology.
CollPlant's distribution agreement in Poland for its VergenixSTR product represents a strategic expansion of the company's European commercial footprint. VergenixSTR leverages CollPlant's proprietary rhCollagen (recombinant human collagen) technology to create a scaffold that works synergistically with platelet-rich plasma (PRP) for treating tendinopathies across multiple indications including tennis elbow, rotator cuff injuries, and Achilles tendon injuries.
The product's differentiated mechanism creates a gel matrix at the injury site that enables controlled release of growth factors while maintaining proper positioning at the target area—addressing key limitations of traditional PRP therapy which often suffers from rapid dispersion and degradation. This controlled-release approach potentially offers superior clinical outcomes compared to standard treatments.
What makes this distribution expansion significant is that it continues CollPlant's systematic market penetration strategy across Europe and Asia-Pacific regions. The Poland agreement follows CollPlant's established pattern of incremental geographic expansion through distribution partnerships rather than building direct sales infrastructure, allowing for capital-efficient commercialization.
The timing indication that first shipments are expected by year-end suggests revenue impact could begin in Q4 2025 or early 2026. While specific financial terms aren't disclosed, this agreement adds another revenue stream to CollPlant's portfolio, which also includes its potentially more substantial partnership with Allergan/AbbVie for dermal and soft tissue fillers established in 2021.
The VergenixSTR product itself addresses a substantial market opportunity across multiple tendinopathy indications, which collectively affect millions of patients annually and represent a significant treatment challenge in orthopedics and sports medicine.
REHOVOT,
Vergenix™ STR is a soft tissue repair matrix specifically designed for combination with platelet-rich plasma (PRP). Upon mixing, it forms a scaffold with delayed degradation and strong retention at the injury site, supporting a localized and sustained therapeutic effect. The product is intended to promote tendon healing across multiple indications, including lateral epicondylitis ('tennis elbow'), rotator cuff injuries, patellar tendinopathy, Achilles tendon injuries, and hand tendon repairs.
Yehiel Tal, Chief Executive Officer of CollPlant, commented: "As we expand our distribution network across
About Vergenix STR
VergenixSTR is a soft tissue repair matrix that combines cross-linked rhCollagen with Platelet-rich plasma, or PRP, a concentrated blood plasma that contains high levels of platelets, a critical component of the healing process. Platelets contain growth factors that are responsible for stimulating tissue generation and repair, including soft tissue repair, bone regeneration, development of new blood vessels, and stimulation of the wound healing process. VergenixSTR serves as a scaffold to support cell proliferation and the release of growth factors. The product is injected into the affected area and forms a viscous gel matrix which serves as a temporary reservoir for PRP in the vicinity of a tendon injury site, holding the platelet concentrate in place at the injured area. The matrix formed has the capabilities to activate the platelets in PRP, thereby releasing growth factors in a controlled manner and controlled biodegradation time, enabling optimal healing.
About CollPlant Biotechnologies
CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing.
In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market.
For more information about CollPlant, visit http://www.collplant.com
Forward-Looking Statements
This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant's objectives plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future such as expectations regarding the market potential of VergenixSTR. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate.
Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company's history of significant losses, its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all, including uncertainties surrounding the methods of fundraising and the Company's preferences regarding such methods; the Company's expectations regarding the costs and timing of commencing and/or concluding pre-clinical and clinical trials with respect to breast implants, tissues and organs which are based on its rhCollagen based BioInk and other products for medical aesthetics, and specifically the Company's ability to initiate its next large-animal study for its breast implants in a timely manner, or at all; the Company's or Company's strategic partners' ability to obtain favorable pre-clinical and clinical trial results, including with respect to the Company's dermal filler product; regulatory action with respect to rhCollagen-based bioink and medical aesthetics products or product candidates including, but not limited to, acceptance of an application for marketing authorization review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based products; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers and the ability to manufacture and supply its products to cover market demands; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations, including its partnership with AbbVie and its ability to continue to receive milestone and royalties payments under the AbbVie agreement; the Company's reliance on third parties to conduct some or all aspects of its product development and manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates, including, with respect to the ongoing war in
Contacts
CollPlant:
Eran Rotem
Deputy CEO & CFO
Tel: + 972-73-2325600
Email: Eran@collplant.com
Investors:
LifeSci Advisors
Dan Ferry
daniel@lifesciadvisors.com
Photo: https://mma.prnewswire.com/media/2772688/COLLPLANT_VergenixSTR.jpg
Logo: https://mma.prnewswire.com/media/2217353/CollPlant_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/collplant-expands-the-distribution-of-its-vergenixstr-product-in-europe-302556086.html
SOURCE CollPlant
FAQ
What is CollPlant's VergenixSTR and how does it work?
Which conditions can CollPlant's VergenixSTR treat?
When will CollPlant (NASDAQ:CLGN) begin distribution of VergenixSTR in Poland?
What is CollPlant's partnership with Allergan about?
How is CollPlant's VergenixSTR different from other tendon treatments?
